Are you making sure your GLPs are made in a US 797 compliant lab?

In the world of pharmaceutical compounding, ensuring compliance with the latest standards is crucial for safety and quality. USP General Chapter <797> outlines specific requirements for compounded sterile preparations (CSPs) to minimize risks of contamination and harm to patients. As of November 1, 2023, new revisions to the guidelines became enforceable, demanding heightened attention and adjustment to laboratory practices. This article explores the key facets of USP 797 compliance, offering insights into environmental monitoring, training, and operational standards that laboratories must uphold.

USP <797> compliance refers to the regulations governing sterile drug compounding in pharmacies to ensure patient safety. This involves performing sterile compounding within an ISO 5 (Class 100) laminar flow hood, which should ideally be situated in a cleanroom maintaining an ISO 7 (Class 10,000) Buffer Zone.

Sterile compounding is classified into three risk categories—Low, Medium, and High—each requiring specific compliance measures:

• Low Risk : Involves simple manipulations, requiring basic precautions.
• Medium Risk : Involves more complex compounding activities, necessitating stricter adherence to protocols.
• High Risk : Involves highly complex processes with significant contaminant exposure, demanding the highest level of compliance.

Proper design is essential, with cleanrooms made from materials like Fiberglass Reinforced Plastic (FRP) and High-Pressure Laminate (HPL) , facilitating a controlled environment that minimizes contamination.

Additionally, compliance with USP <797> aligns with Current Good Manufacturing Practices (CGMP), including ongoing air quality and cleanliness monitoring crucial to safe drug preparation.

To access USP General Chapter <797>, visit the USP Compounding Compendium website, as the transition to an online platform occurred on November 1, 2023. The chapter is no longer available in PDF format, reflecting updated practices in healthcare safety standards.

The compendium also provides valuable educational resources, including FAQs and commentary to help professionals navigate the revised standards effectively. Staying abreast of these updates is crucial for ensuring compliance and maintaining patient safety during sterile compounding.

Staying informed about USP <797> changes is vital due to its considerable impact on patient safety in compounding practices. Regularly checking for updates through the compendium can assist personnel in adhering to best practices and mitigating contamination risks.

Yes, USP <797> applies to physician offices that engage in sterile compounding. This regulation is designed to ensure the safe preparation and handling of sterile medications, aiming to minimize contamination and errors. Any healthcare facility, including physician offices, that prepares sterile products must follow these guidelines to maintain patient safety and ensure proper compounding practices.

Compliance with USP <797> is crucial in all settings where sterile preparations are made, including physician offices. The handling and administration of medications, such as lenograstim, require adherence to stringent protocols. Effective practices like routine surface testing, personnel sampling, and environmental monitoring are essential to safeguard the sterility of compounded products.

Physician offices must implement thorough training for staff on proper garbing and compounding techniques. Daily cleaning procedures and regular assessments of the cleanroom conditions help to align with USP <797>. Moreover, embracing web-based systems for training and documentation can enhance compliance efforts and streamline processes in these healthcare environments.

To achieve compliance with USP <797>, the IV compounding room must maintain at least ISO Class 7 air quality. This involves having a positive air pressure differential of a minimum of 0.01 inch water column in relation to adjacent areas. Such measures help to prevent contamination from the surrounding environment.

The room should be equipped with a HEPA filtration system that effectively captures airborne particles as small as 0.3 microns. Smooth and non-porous surfaces are essential for easy cleaning and disinfection, preventing debris accumulation that could harbor microorganisms.

It's also important for the IV room to feature a hand hygiene sink with touch-free faucets and designated storage areas for sterile and non-sterile supplies. This setup promotes efficient hygiene practices and organization within the compounding space.

Regular environmental monitoring is crucial. This includes air and surface sampling and continuous monitoring of pressure differentials between classified areas to address any potential risks quickly.

Personnel working in the IV room must undergo rigorous training in aseptic techniques. This includes understanding the protocols for garbing, cleaning, and monitoring their hygiene practices. Initial competency testing is required, which can involve observational assessments to ensure adherence to guidelines.

Additionally, glove fingertip sampling is mandatory. Staff must demonstrate effective hand hygiene, with benchmarks in place for the acceptable level of microbial contamination. Routine training updates and competency evaluations are essential to maintain compliance and ensure patient safety in sterile compounding environments.

Routine personnel training is crucial for maintaining compliance with USP 797 standards. It serves as a preventative measure against human error, which is a common risk factor in sterile environments. Training programs should include initial evaluations and periodic re-assessments of staff on essential topics such as:

• Aseptic techniques
• Gowning procedures
• Contamination prevention measures

Employees must understand specific tasks in their roles and demonstrate high competency in maintaining sterile conditions. Regular glove fingertip sampling and environmental monitoring through air and surface assessments are also required, ideally taking place every six months to maintain stringent compliance.

Environmental testing is vital under USP 797 as it identifies potential microbial contamination sources, safeguarding the sterility of compound preparations. Cleanroom environments must undergo routine checks, which include:

• Air sampling
• Surface sampling
• Glove fingertip testing

These assessments must yield results showing less than 3 CFU (Colony-Forming Units) to demonstrate adherence to safety standards. By continuously monitoring environmental conditions, compounding pharmacies can effectively manage contamination risks, ensuring the safety of pharmaceuticals produced.

The revised USP 797 guidelines, effective November 1, 2023, introduce significant changes aimed at enhancing the safety and quality of compounded sterile preparations (CSPs). Among these changes:

• Increased Environmental Monitoring : There's now a requirement for more frequent environmental monitoring, particularly in cleanroom environments.
• Microbial Identification : Facilities must identify microorganisms to the genus level, highlighting the importance of understanding contamination risks.
• Updated Cleanroom Standards : Revisions to cleanroom requirements will also affect the protocols followed by compounding personnel.

These changes underscore the necessity for compounding pharmacies to review and update their standard operating procedures (SOPs) accordingly, ensuring all staff members are adequately trained on the new compliance standards. Non-compliance will be closely monitored by state pharmacy boards, which can impose penalties for violations.

The updates to the USP 797 guidelines necessitate substantial changes across laboratory workflows. Operations are affected in numerous ways:

• Training and Competency : Regular training sessions for the compounding staff must be increased to familiarize them with the new procedures, which could require additional time and resources.
• Workflow Optimization : Facilities have the chance to enhance their operations beyond mere compliance. This includes improving safety measures and operational efficiencies.

These adjustments are essential for ensuring compliance and safeguarding patient care. A proactive approach to these revisions will benefit laboratories in maintaining high standards of safety and quality.

Adhering to USP 797 standards is no longer optional but an essential component in ensuring the safety and efficacy of compounded sterile preparations. Laboratories that prioritize and consistently practice these compliance measures not only safeguard patient health but also fortify their operational credibility. With the full enforcement of the updated guidelines, it becomes ever more imperative to integrate these standards into daily compounding practices, fostering a culture of vigilance and excellence in pharmaceutical compounding.

• 7 clean room guidelines to know for USP 797 - Wolters Kluwer
• USP <797> Compliance: It's as Easy as A,B,C...1,2,3. Or is it?
• Testing Compliance in the 2023 Pharmacy Cleanroom
• USP 797 Personnel And Surface Testing – Staying Compliant In 2023
• Tips for complying with USP 797
• Key USP 800 Compliance Points: Healthcare Labs & Pharmacies
• How To Meet UPS 797 & USP 800 Compliance Standards
• USP : Conforming to the Rules, Understanding Inherent Risks